Blog

When Pfizer announced it would pay up to $495 million to commercialize Sciwind Biosciences’ GLP-1 agonist ecnoglutide in China, most coverage focused on deal size and market share. But from a manufacturing and API sourcing perspective, this move signals something deeper: The center of gravity for next-generation GLP-1 production is shifting toward integrated Chinese chemical supply chains. At UTIDECHEM, we operate upstream—where peptide resins, protected amino acids, linkers, and coupling systems determine whether a molecule scales smoothly or collapses under cost pressure. This article breaks down what the Pfizer-Sciwind deal really means for chemistry, cost structures, and supply chain strategy. 1. Why Ecnoglutide’s “Bias” Is More Than Marketing Ecnoglutide is designed as a cAMP-biased GLP-1 receptor agonist. In practical terms, this means the molecule preferentially activates

Although China’s polypeptide cosmetics market started relatively late, its unique market dynamism and rapidly iterating local innovations have made it one of the fastest-growing segments in the global beauty industry. While international brands hold a first-mover advantage in peptide ingredient R&D, their technological accumulation has not translated into market dominance, constrained by misaligned strategies and insufficient localization. In contrast, domestic brands such as Kans (韩束) have successfully captured consumer mindshare through precise positioning and technological breakthroughs, driving the market toward a “domestic-led, multi-polar competitive” landscape. As of 2025, the market remains in the early stage of rapid growth, with both technological dividends and rising consumer demand yet to be fully realized.

As polypeptide drugs, represented by GLP-1, expand their applications across numerous chronic diseases—such as diabetes, weight management, chronic kidney disease, cardiovascular diseases, and osteoarthritis—their market potential is rapidly increasing. According to Sullivan data, measured by sales revenue, the global polypeptide drug market is expected to grow from USD 60.7 billion in 2018 to USD 261.2 billion by 2032. Moreover, 2014–2026 marks a peak period for patent expirations of major polypeptide drugs, which will lead to a wave of generics and accelerate pharmaceutical companies’ development of next-generation polypeptides. As old and new molecules compete in the same arena, reconstruction of synthetic processes and compliant capacity expansion will naturally propagate up the value chain, creating new opportunities for upstream companies controlling key R&D and production technologies, including intermediates

I. Why Polypeptides Must Be Discussed Today Over the past 12 months, the hottest pharmaceutical keyword in global capital markets has not been ADCs or gene therapy—it has been “polypeptides.” From social media buzz over “miracle weight-loss drugs” to multinational pharmaceutical companies placing multi-billion-dollar capacity expansion orders, and from provincial “15th Five-Year Plan” bioeconomy strategies in China listing “polypeptide APIs and formulations” as priority tracks—the signals are clear: polypeptide drugs have entered a phase of triple resonance—policy, technology, and capital. The Zhongyan Puhua Research Institute recently released the 2025–2030 Polypeptide Drug Industry Market Deep Research and Investment Value Analysis Report (hereinafter referred to as the Report), which continuously tracks four major global databases: patents, clinical trials, production capacity, and policy. The conclusion is straightforward: “Over the

Polypeptides are compounds formed by multiple amino acids linked through peptide bonds, typically consisting of 10 to 100 amino acids with a molecular weight below 10,000. Polypeptides are widely present in living organisms and play important roles in regulating the functions of various systems, organs, tissues, and cells. With advances in biotechnology and polypeptide synthesis, more polypeptide-based drugs have been developed and applied clinically, becoming new treatment options for a variety of diseases. I. Current Status of the Polypeptide Drug Industry1.1 Market Size and Growth Trends In recent years, the global polypeptide drug market has shown significant growth. According to the 2024-2029 China Polypeptide Drug Industry Deep Research and Investment Opportunity Analysis Report by Zhongyan Puhua Research Institute, the global polypeptide drug market grew from USD